Researchers identify key factors for successful donor lymphocyte infusion in AML patients

Dana-Farber Cancer Institute researchers have identified factors that determine whether donor lymphocyte infusion (DLI), a standard therapy for patients with acute myeloid leukemia (AML) who have relapsed after allogenic hematopoietic stem cell transplant, will successfully move the patient into remission.

CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities – Biotech Investments

Issuer: CureVac / Key word(s): Restructure of Company/Strategic Company Decision 03.07.2024 / 08:12 CET/CEST The issuer is solely responsible for the content of this announcement.

July 4, 2024

The latest obesity drug updates happening right now

This story first appeared in The Readout newsletter. Sign up for The Readout and receive STAT’s award-winning biotech news delivered straight to your inbox. Good morning. I’m still in

October 1, 2024

Revive Therapeutics Provides (Yet Another) Update on Bucillamine for Nerve Agent Exposure | Psychedelic Invest

TORONTO, Aug. 28, 2024 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused

August 28, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.